Cargando…

TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases

Aberrant tumour necrosis factor (TNF) signalling is a hallmark of many inflammatory diseases including rheumatoid arthritis (RA), irritable bowel disease and lupus. Maladaptive TNF signalling can lead to hyper active downstream nuclear factor (NF)-κβ signalling in turn amplifying a cell's infla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Totzke, Juliane, Scarneo, Scott A., Yang, Kelly W., Haystead, Timothy A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536066/ https://www.ncbi.nlm.nih.gov/pubmed/32873150 http://dx.doi.org/10.1098/rsob.200099

Ejemplares similares

Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice
por: Scarneo, Scott A., et al.
Publicado: (2019)

Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion
por: Scarneo, Scott A., et al.
Publicado: (2018)

Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis
por: Freeze, Robert, et al.
Publicado: (2023)

TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades
por: Scarneo, Scott A., et al.
Publicado: (2020)

Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis
por: Bale, Swarna, et al.
Publicado: (2023)

Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
por: Imaeda, Yasuhiro, et al.
Publicado: (2016)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome
por: Lepzien, Rico, et al.
Publicado: (2021)

Tumour necrosis factor-dependent inflammatory cartilage destruction
por: Korb, A, et al.
Publicado: (2007)

TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma
por: Campolo, Michela, et al.
Publicado: (2020)

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
por: Patel, Serena, et al.
Publicado: (2021)

A stonemason with accelerated silicosis in the setting of tumour necrosis factor alpha inhibitor therapy
por: Baird, Timothy, et al.
Publicado: (2016)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
por: Lieu, Christopher H., et al.
Publicado: (2015)

Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease
por: Ślebioda, Tomasz J., et al.
Publicado: (2014)

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
por: Crowe, J. Scott, et al.
Publicado: (2018)

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
por: Eberhardson, Michael, et al.
Publicado: (2022)

Blocking connexin43 hemichannels protects mice against tumour necrosis factor-induced inflammatory shock
por: Delvaeye, Tinneke, et al.
Publicado: (2019)

Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist
por: Fujimoto, Tatsuhiko, et al.
Publicado: (2022)

Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee
por: Maksymowych, Walter P, et al.
Publicado: (2012)

TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation
por: Morioka, Sho, et al.
Publicado: (2014)

Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
por: Yahya, Fariz, et al.
Publicado: (2019)

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors
por: Maraspin, Vera, et al.
Publicado: (2019)

Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor
por: Chey, Shin Yee, et al.
Publicado: (2022)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Tumor necrosis factor-α blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
por: Van den Bosch, Filip, et al.
Publicado: (2005)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha
por: Seow, W. Kim, et al.
Publicado: (1993)

The Prevalence of TNFα-Induced Necrosis over Apoptosis Is Determined by TAK1-RIP1 Interplay
por: Çöl Arslan, Seda, et al.
Publicado: (2011)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization
por: Assas, B. M., et al.
Publicado: (2016)

Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
por: Cairns, A. P., et al.
Publicado: (2002)

Opioid receptor expression on neutrophils: effect of tumour necrosis factor alpha treatment
por: Schmidt, A, et al.
Publicado: (2007)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
por: Miles, D. W., et al.
Publicado: (1992)

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
por: Pappas, Dimitrios A, et al.
Publicado: (2021)

Tumour necrosis factor in man: clinical and biological observations.
por: Selby, P., et al.
Publicado: (1987)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jrleqlub5t0m9uk4htvl20g8kk